SCHEMBL3003206

SCHEMBL3003206

O=S(=O)(c1ccc(F)cc1Cl)N1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.66
L3MBTL1 Q9Y468 3/20 0.66
ALDH1A1 P00352 2/20 0.66
MAPT P10636 7/20 0.63
LMNA P02545 6/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
MAPK1 P28482 5/20 0.61
AR P10275 3/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009390 0.93 SMN1; SMN2 (0.65) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3007066 0.92 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3020065 0.92 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3013888 0.92 SMN1; SMN2 (0.64) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3016755 0.92 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL2998650 0.92 SMN1; SMN2 (0.66) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3002184 0.91 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3006401 0.91 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL3015864 0.91 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL2998039 0.90 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.